MOLNMOLECULAR PARTNERS AG

Nasdaq molecularpartners.com


$ 6.61 $ -0.07 (-0.97 %)    

Tuesday, 09-Jul-2024 14:49:04 EDT
QQQ $ 492.14 $ -11.98 (-2.38 %)
DIA $ 397.90 $ 0.37 (0.09 %)
SPY $ 556.42 $ -4.90 (-0.87 %)
TLT $ 93.53 $ 0.89 (0.96 %)
GLD $ 223.19 $ 3.89 (1.77 %)
$ 6.7
$ 6.73
$ 0.00 x 0
$ 6.80 x 200
$ 6.61 - $ 6.73
$ 3.32 - $ 12.70
3,385
na
243.57M
$ 1.06
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
Market-Moving News for June 14th
06/14/2024 12:34:25

ADBE: 16% | Adobe shares are trading higher following better-than-expected Q2 earnings and strong guidance. BPTH: 46% | Bio-Pa...

 molecular-partners-reveals-preclinical-data-for-first-switch-darpin-candidate-mp0621-at-eha-2024

Proof-of-concept of Switch-DARPin platform established in vivo, enabling the use of logic-gated and reversible immune activat...

Core News & Articles
Market-Moving News for June 11th
06/11/2024 12:29:09

MOLN: 11% | Molecular Partners shares are trading higher after the company announced the debut of their lead Raido-DARPin thera...

 reported-saturday-molecular-partners-presented-data-from-completed-phase-1-trial-of-mp0317-monotherapy-in-advanced-solid-tumors-at-asco-2024

Mechanism of action supported by observed MP0317 localization and immune cell activation in the tumor microenvironment Favor...